Felipe
Prosper Cardoso
Consultor Médico
Hospital Universitario de Salamanca
Salamanca, EspañaPublicaciones en colaboración con investigadores/as de Hospital Universitario de Salamanca (53)
2024
-
Biomarkers of Efficacy and Safety of the Academic BCMA-CART ARI0002h for the Treatment of Refractory Multiple Myeloma
Clinical Cancer Research, Vol. 30, Núm. 10, pp. 2085-2096
-
PVR (CD155) epigenetic status mediates immunotherapy response in multiple myeloma
Leukemia
-
Round Table Discussion on Optimal Clinical Trial Design in Precursor Multiple Myeloma
Blood cancer discovery, Vol. 5, Núm. 3, pp. 146-152
-
Single-cell transcriptional profile of CD34+ hematopoietic progenitor cells from del(5q) myelodysplastic syndromes and impact of lenalidomide
Nature Communications, Vol. 15, Núm. 1
2023
-
Epigenome profiling reveals aberrant DNA methylation signature in GATA2 deficiency
Haematologica, Vol. 108, Núm. 9, pp. 2551-2557
-
Fractionated initial infusion and booster dose of ARI0002h, a humanised, BCMA-directed CAR T-cell therapy, for patients with relapsed or refractory multiple myeloma (CARTBCMA-HCB-01): a single-arm, multicentre, academic pilot study
The Lancet Oncology, Vol. 24, Núm. 8, pp. 913-924
-
Integrated flow cytometry and sequencing to reconstruct evolutionary patterns from dysplasia to acute myeloid leukemia
Blood Advances, Vol. 7, Núm. 1, pp. 167-173
-
Phase I study of plitidepsin in combination with bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma
Cancer Medicine, Vol. 12, Núm. 4, pp. 3999-4009
-
Transcriptional and genomic characterization of measurable residual disease in acute myeloid leukaemia
British Journal of Haematology
-
Uncovering perturbations in human hematopoiesis associated with healthy aging and myeloid malignancies at single-cell resolution
eLife, Vol. 12
2022
-
Circulating Tumor and Immune Cells for Minimally Invasive Risk Stratification of Smoldering Multiple Myeloma
Clinical cancer research : an official journal of the American Association for Cancer Research, Vol. 28, Núm. 21, pp. 4771-4781
-
Lenalidomide-dexamethasone versus observation in high-risk smoldering myeloma after 12 years of median follow-up time: A randomized, open-label study
European Journal of Cancer, Vol. 174, pp. 243-250
-
Optimization of Mesenchymal Stromal Cell (MSC) Manufacturing Processes for a Better Therapeutic Outcome
Frontiers in Immunology, Vol. 13
-
Preneoplastic somatic mutations including MYD88L265P in lymphoplasmacytic lymphoma
Science Advances, Vol. 8, Núm. 3
-
Prognostic impact of micromegakaryocytes in primary myelodysplastic syndromes
Leukemia and Lymphoma, Vol. 63, Núm. 5, pp. 1227-1235
-
The transcription factor DDIT3 is a potential driver of dyserythropoiesis in myelodysplastic syndromes
Nature Communications, Vol. 13, Núm. 1
2021
-
Endobronchial autologous bone marrow-mesenchymal stromal cells in idiopathic pulmonary fibrosis: a phase I trial
ERJ Open Research, Vol. 7, Núm. 2, pp. 00773-2020
-
Immunogenetic characterization of clonal plasma cells in systemic light-chain amyloidosis
Leukemia, Vol. 35, Núm. 1, pp. 245-249
-
Long-term efficacy of autologous bone marrow mesenchymal stromal cells for treatment of knee osteoarthritis
Journal of Translational Medicine
-
Measurable residual disease in elderly acute myeloid leukemia: Results from the PETHEMA-FLUGAZA phase 3 clinical trial
Blood Advances, Vol. 5, Núm. 3, pp. 760-770